Abstract
Gonorrhea rates have increased 111% in the U.S. since 2009, and gonorrhea’s ability to rapidly develop antimicrobial resistance has left clinicians with few options for treatment. Recent observational studies have suggested that a serogroup B meningococcal vaccine may also be partially effective against gonococcal infection. In this paper, we calculate the dynamic optimal mixture of vaccination and screening interventions for population-level gonorrhea control.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
